A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

(2010) Karen Edmond et al.   LANCET INFECTIOUS DISEASES

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

(2010) Dlawer A.A. Ala’Aldeen et al.   VACCINE

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Quadrivalent meningococcal conjugate vaccines

(2009) David Pace et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Epidemiologic and Microbiologic Characteristics of Recurrent Bacterial and Fungal Meningitis in The Netherlands, 1988–2005

(2008) Joris J. van Driel et al.   CLINICAL INFECTIOUS DISEASES